Geode Capital Management
BDTX icon

Geode Capital Management’s Black Diamond Therapeutics BDTX Stock Holding History

Geode Capital Management’s Portfolio BDTX Stock Details BDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.25M Buy
1,218,171
+681,596
+127% +$1.67M ﹤0.01% 3166
2026
Q1 		$1.14M Buy
536,575
+30,795
+6% +$73.2K ﹤0.01% 3321
2025
Q4 		$1.23M Buy
505,780
+5,257
+1% +$18.6K ﹤0.01% 3316
2025
Q3 		$1.9M Buy
500,523
+5,180
+1% +$15.2K ﹤0.01% 3195
2025
Q2 		$1.23M Sell
495,343
-470,256
-49% -$906K ﹤0.01% 3269
2025
Q1 		$1.5M Buy
965,599
+6,283
+0.7% +$13.2K ﹤0.01% 3156
2024
Q4 		$2.05M Buy
959,316
+14,439
+2% +$41.4K ﹤0.01% 3112
2024
Q3 		$4.11M Buy
944,877
+102,445
+12% +$557K ﹤0.01% 2864
2024
Q2 		$3.93M Buy
842,432
+459,819
+120% +$2.47M ﹤0.01% 2857
2024
Q1 		$1.94M Buy
382,613
+32,167
+9% +$130K ﹤0.01% 3123
2023
Q4 		$985K Buy
350,446
+26,155
+8% +$61.4K ﹤0.01% 3363
2023
Q3 		$931K Buy
324,291
+53,084
+20% +$196K ﹤0.01% 3352
2023
Q2 		$1.37M Buy
271,207
+779
+0.3% +$1.59K ﹤0.01% 3235
2023
Q1 		$511K Buy
270,428
+5,138
+2% +$11.8K ﹤0.01% 3637
2022
Q4 		$477K Buy
265,290
+743
+0.3% +$1.34K ﹤0.01% 3679
2022
Q3 		$447K Buy
264,547
+17,839
+7% +$55K ﹤0.01% 3778
2022
Q2 		$606K Sell
246,708
-185,316
-43% -$431K ﹤0.01% 3653
2022
Q1 		$1.2M Buy
432,024
+35,857
+9% +$131K ﹤0.01% 3530
2021
Q4 		$2.11M Buy
396,167
+46,187
+13% +$323K ﹤0.01% 3338
2021
Q3 		$2.96M Sell
349,980
-9,622
-3% -$95K ﹤0.01% 3187
2021
Q2 		$4.38M Buy
359,602
+62,165
+21% +$1.23M ﹤0.01% 2984
2021
Q1 		$7.21M Buy
297,437
+27,512
+10% +$742K ﹤0.01% 2585
2020
Q4 		$8.65M Buy
269,925
+22,199
+9% +$729K ﹤0.01% 2273
2020
Q3 		$7.49M Buy
247,726
+65,962
+36% +$2.01M ﹤0.01% 2144
2020
Q2 		$7.66M Buy
181,764
+91,367
+101% +$3.36M ﹤0.01% 2090
2020
Q1 		$2.25M Buy
+90,397
New +$2.75M ﹤0.01% 2609

Other funds holding BDTX

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
DCM
Defilade Capital Management Emeryville, California $747M AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $52.8B AUM 58.98% 1-Year Est. Return
AIC
AWM Investment Company New York $1.15B AUM 201.65% 1-Year Est. Return

Geode Capital Management's BDTX Position: Q2 2026 in Review

Geode Capital Management increased its Black Diamond Therapeutics (BDTX) stake by 127% in Q2 2026, buying an estimated $1.67M and bringing the position to 1,218,171 shares worth $2.25M. The position accounts for ﹤0.01% of the portfolio, ranked #3166.

Geode Capital Management first reported a position in BDTX in Q1 2020 and has held it in 26 quarters since. The position peaked at $8.65M in Q4 2020. 96 funds tracked by Wall St. Rank hold BDTX as of Q2 2026.

  • Geode Capital Management held 1,218,171 shares of Black Diamond Therapeutics worth $2.25M as of Q2 2026.
  • Geode Capital Management bought 681,596 Black Diamond Therapeutics shares in Q2 2026, an estimated $1.67M.
  • Black Diamond Therapeutics made up ﹤0.01% of Geode Capital Management's portfolio in Q2 2026, its #3166 holding.
  • Geode Capital Management first reported a position in Black Diamond Therapeutics in Q1 2020 and has held it in 26 quarters since.
  • Geode Capital Management's Black Diamond Therapeutics position peaked at $8.65M in Q4 2020.
  • 96 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q2 2026.

Based on Geode Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.